Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus

By sjmartinez • November 30, 2023

Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023 Oct 31;14:1242830. doi: 10.3389/fendo.2023.1242830. PMID: 38027216; PMCID: PMC10643762.

Tags: autoimmune endocrinopathy, Endocrinology, General Internal Medicine, Hematology/Oncology, immune checkpoint inhibitor, immune related adverse events, Olive View DoM, Publications, safety, type 1 diabetes mellitus

Increasing Diversity in the Nutrition, Obesity, and Diabetes Biomedical Workforce: The BRIDGES Consortium

Newton RL Jr, Katzmarzyk PT, Duru OK, Lee A, Irwin A, Mangione CM, Morone NE, Ongeri EM, Shaikh SR, Stanford FC, Stanley TL, Truesdale KP;[...]

Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid Cancer Treatment

Huston-Paterson HH, Mao YV, Hughes EG, Bobanga I, Wu JX, Yeh MW. Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid[...]

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Perry AS, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, Stolze LK, Betti MJ, Zhao S, Huang S, Martens L, Kendall TJ, Thone[...]